## Genomics England Limited –Board Meeting

## Minutes of Meeting held on 18 September 2018

|  |  |
| --- | --- |
| Present: | Sir John Chisholm (JC) (Chair) |
|  | Prof John Mattick (Chief Executive) |
|  | Prof Sir John Bell (JB) |
|  | Prof Ewan Birney (EB) |
|  | Prof Mark Caulfield (MC) |
|  | Prof Dame Kay Davies (KD) |
|  | Prof Sir Malcolm Grant (MG) |
|  | Kristen McLeod (KM) |
|  | Steve Oldfield (SO) |
|  | Prof Michael Parker (MP) |
|  | Prof Keith Stewart (KS) |
|  | Jon Symonds (JS) |
|  | Nick Maltby (NM) |
|  |  |
| In attendance: | Mark Bale (MB) |
|  | Peter Counter (PC) |
|  | Graham Colbert (GC) |
|  | Joanne Hackett (JH) |
|  | John Hatwell (JXH) |
|  | Prof Dame Sue Hill (SH) |
|  | Augusto Rendon (AR) |
| Apologies: | Prof Dame Sally Davies (SD) |
|  | Sir Ron Kerr (RK) |
|  |  |

**18-19/036 – Apologies:** See above.

**18-19/037– Chair’s Introduction:** JC welcomed the directors to the meeting.

**18-19/038– Declarations of Conflicts of Interest:** JC reminded the Board that all conflicts needed to be declared.

**18-19/039– Approval of the Minutes of the June Board Meeting and Actions Arising**

The minutes of the June Board Meeting were approved. NM was authorised sign the minutes as a true record of the meeting. The actions arising were as follows:

|  |  |  |
| --- | --- | --- |
| **ACTION** | **OWNER** | **STATUS** |
| Send Register of Interests to new directors | NM | Done |
| Bring a corporate plan to September Board | JM | Will now be November |
| Discuss the commercial report earlier in the agenda at the next Board meeting. | JC | We will develop a commercial strategy alongside the corporate plan and bring it to a BIC in the next couple of months. |
| JC on behalf of the Board to congratulate Sue Hill formally on her DBE. | JC | Done |

**18-19/040 Chief Executive’s Report**

* JM informed the Board that he felt he was now getting to grips with the landscape. It was noted that JM’s arrival had been well received by the community.
* There followed a discussion of the relationship with CRUK.
* JM confirmed that his next CEO report will set out issues he wants to consider for the future. The main agenda item will be the GeL corporate plan.

**18-19/041 Update on UK National Vision and Plan (JM)**

* JM introduced the vision document. The 5m target requires a bringing together of the 3 strands (NHS, research and commercial cohorts). This will be taken to the National Genomic Board sub-cttee on Friday. The NHS contribution will be driven by the clinical service. Hubs will be asked to opt for WGS not WES. GeL needs to get the cost of WGS to a level to allow NHS services to be upgraded to WGS and to move to a more health management service rather than a crisis management service.
* The essence of the vision is contained in the Preamble. The key question for the system is what is the appetite in the next 5 years to build on the good start of the 100KGP and what is the role of GeL in this landscape? JM invited Board comments on the plan/endorsement.
* There followed a discussion of the Vision and Plan.
* **The Board endorsed the vision but agreed the plan needs work.** It was agreed that we now need to act very quickly. **Action: We will take the comments on board and update the Vision document.**

**18-19/042 – [Confidential item]**

* [Redacted]

**18-19/043 – Joint Operations Report**

* SH commented that we can anticipate 66K RD samples in UKB by the end of September (213 RD categories) from 26.5k families. GMCs are forecast to meet the cancer forecast by end Dec (24 cancer types across 162 Trusts). . NHSE will be around 6K over the target of 90K samples. The Increased diagnostic yield (over standard care) is 25%, ranging as high as 50% in ophthalmic disease. The Board congratulated GeL and NHSE on this progress. NHSE will produce a paper showing the implications for transition and other costs.
* It was noted that rare disease recruitment is really strong and ahead of budget. We need to work out how to deal with that.
* We are now aiming for an even flow of results back to GMCs.
* It was noted that Ministers will want to celebrate reaching the 100KGP..
* There followed a discussion as to performance of the clinical interpretation providers.

**18-19/044 – GMS Preparations (SH/PC)**

* SH then took the Board through her paper. NHSE is in final stages of the GLH procurement. There will be an interim arrangement until April. GLHs have responded well to the requirement for consolidation, standardisation and a more consistent approach.
* From the beginning of October 2018 there will be a move to test directory.
* NHSE is in discussion with GeL about WGS provision particularly with regard to the price point and turnaround times.
* [Confidential matter – redacted].

**18-19/045 – Finance Report**

* There was a discussion of GC’s finance report including the cost of delivering NGIS.
* GC commented that we are still coming in around the £200m agreed for the 100KGP.
* There followed a discussion of the numbers in the Vision. **Action: schedule an Audit Committee in the next fortnight to discuss the numbers in the Vision and the Forecast**.
* It was also noted that we need to sort out a DHSC finance representative to be a member. **Action: KM to advise who from DH Finance might join the GeL Audit Committee**.
* GC noted that we have asked DHSC for an additional budget payment of £30m. As usual GeL will issue shares for the contribution. **The Board accordingly resolved to issue 30m additional shares of £1 only in return for the payment.**

**18-19/046 –Corporate Services Report: t**here was no discussion of the Corporate Services Report.

**18-19/047 - Science, Ethics and GeCIP Report (MC):**

* MC noted that over £20m has now been raised for research.
* UK Life Science strategy: MC drew the Board’s attention to the projects and matched funding on page 4 of his report.

**18-19/048 - Bioinformatics Report (AR):**

* We are now demonstrating very large throughputs.
* The next ISO visit is in Oct/Nov. We are conducting a new round of validation to make sure we are ready.

**18-19/049– Commercial Report (JH):**

* We have 5 fee paying members for the Discovery Forum and 7 commercial GeCIPs in the pipeline.
* We have Open Targets as one of the platforms we are developing in the environment.
* We finally signed the IQVIA contract on 17 September. We will be collaborating on a clinical trials platform; analysis; and research exploration with IQVIA.
* There are now over 55k genomes in the Research Environment.
* It was confirmed that we don’t yet ave the ability to add prescription data.
* MC noted that GeL will bring a detailed commercial strategy to a future BIC meeting and then to the Board.

**18-19/050 - Communications Report (GC): t**here was no discussion of the Communications Report.

**18-19/051 – DPO Report (NM):** there was no discussion of the DPO Report.

**18-19/052 - Board Committees**: there was no discussion of the Board Committee minutes.

**18-19/053- Any Other Business:** It was noted that this was MG’s last meeting. JC gave a vote of thanks for his role and the central role of NHS partnership.

**18-19/054 - Date, Time and Agenda for Next Meeting**

**IT WAS NOTED that the next Board meeting would be held on Wednesday 21 November 2018 between 14.00 – 17.00 at Genomics England in Carthusian Street.**

**Close: The meeting closed at 1710**.

…………………………………………………. ……………………………………………………..

Signed Dated